



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68	A1	(11) International Publication Number: WO 99/15700 (43) International Publication Date: 1 April 1999 (01.04.99)
<p>(21) International Application Number: PCT/US98/19549</p> <p>(22) International Filing Date: 22 September 1998 (22.09.98)</p> <p>(30) Priority Data: 08/937,063 24 September 1997 (24.09.97) US</p> <p>(71) Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER [US/US]; 330 Brookline Avenue, Boston, MA 02215 (US). CORNELL RESEARCH FOUNDATION, INC. [US/US]; Suite 105, 20 Thornwood Drive, Ithaca, NY 14850 (US).</p> <p>(72) Inventors: STROM, Terry, B.; 22 Kennard Road, Brookline, MA 02146 (US). VASCONCELLOS, Lauro; 185 Freeman Street, Brookline, MA 02146 (US). SUTHANTHIRAN, Manikkam; Apartment 12N, 1161 York Avenue, New York, NY 10021 (US).</p> <p>(74) Agents: HOGLE, Doreen, M. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).</p>		<p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: METHODS OF EVALUATING TRANSPLANT REJECTION</p>		
<p>(57) Abstract</p> <p>The invention relates to methods of evaluating transplant rejection in a host comprising determining a heightened magnitude of gene expression of two out of three immune activation marker genes perforin, granzyme B and Fas ligand, in a tissue biopsy or peripheral blood mononuclear cell sample, particularly using reverse transcription polymerase chain reaction; methods of assessing antirejection therapy; and kits for use in evaluating transplant rejection.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

METHODS OF EVALUATING TRANSPLANT REJECTION

BACKGROUND OF THE INVENTION

Despite recent improvements in renal allograft survival, the loss of graft function due to acute and chronic rejection continues and is a leading cause of end-stage renal failure today. As the occurrence of acute rejection episodes is the most powerful predictive factor for the later development of chronic rejection in adults and children, many advocate strategies to detect and ablate acute rejection episodes as early as possible.

Procedures to diagnose renal allograft rejection depend upon detection of graft dysfunction and the presence of a mononuclear leukocytic infiltrate. However, the presence of a modest cellular infiltrate is often not conclusive and can be detected in non-rejecting grafts. It would be helpful to have a reliable tool for diagnosis and follow-up of acute renal allograft rejection.

SUMMARY OF THE INVENTION

The present invention relates to methods of monitoring the status of a transplanted organ in a host. More specifically, the present invention relates to evaluating transplant rejection in a host comprising determining the magnitude of gene expression of the immune activation markers perforin (P), granzyme B (GB), and Fas ligand (FasL) genes, in a post-transplant biological sample obtained from the host and comparing the relative expression of the marker genes to a baseline level of expression of the immune activation marker, wherein upregulation of gene expression (i.e., increased or heightened gene expression) of two of the three immune activation marker genes in the sample indicates rejection. Immune activation genes are also referred to herein as cytotoxic lymphocyte (CTL) effector molecules. The methods described herein are particularly useful to detect acute transplant rejection.

-2-

Most typically, the host (i.e., the recipient of a transplant) is a mammal, such as a human. The transplanted organ can include any transplantable organ or tissue, for example kidney, liver, heart, lung or bone marrow.

The post-transplant biological sample (or test sample) from the host can be
5 any biological sample comprising cells that contain RNA (i.e., transcripts) encoding the immune activation marker genes of interest. For example, the sample can be a tissue biopsy sample, or a peripheral blood sample containing mononuclear cells. Additionally, the sample can be lymphatic fluid, peritoneal fluid or pleural fluid. The tissue biopsy sample can be allograft tissue or xenograft tissue. In one
10 embodiment of the present invention, the sample is obtained from a renal allograft.

The magnitude of expression of the immune activation marker genes is determined by quantifying immune activation marker gene transcripts and comparing this quantity to the quantity of transcripts of a constitutively expressed gene. The term "magnitude of expression" means a "normalized, or standardized
15 amount of gene expression". For example, the overall expression of all genes in cells varies (i.e., is not constant). The observation of the increased expression of a gene, as determined by an increase in the presence of an mRNA transcript, must be put into the proper context to accurately assess whether the detection of increased transcript is significant. That is, there must be some way to "normalize" gene
20 expression to accurately compare levels of expression between samples. This can be accomplished by determining the level of expression of the gene of interest (e.g., determining gene mRNA or cDNA transcribed from the gene mRNA) and the level of expression of a universally, or constitutively expressed gene (e.g., a gene that is present in all tissues and has a constant level of expression), and comparing the
25 relative levels of expression between the target gene (gene of interest) and the constitutively expressed gene. In one embodiment, the constitutively expressed gene is glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Other constitutively expressed genes, such as actin, are known to those of skill in the art and can be suitable for use in the methods described herein. In the methods
30 described herein, quantification of gene transcripts was accomplished using

competitive reverse transcription polymerase chain reaction (RT-PCR) and the magnitude of gene expression was determined by calculating the ratio of the quantity of gene expression of each immune activation marker gene to the quantity of gene expression of the constitutively expressed gene. That is, the magnitude of target gene expression is calculated as pg of target gene cDNA per pg of constitutively-expressed gene cDNA.

In one embodiment, the discriminatory level for heightened gene expression (e.g., the baseline magnitude of gene expression) of the immune activation marker gene is set to the mean \pm 95% confidence interval of a group of values observed in nonrejecting transplants (e.g., control values). Heightened gene expression is determined as above a mean \pm 95% confidence interval of these values.

In another embodiment, sequential samples can be obtained from the host and the quantification of immune activation gene markers determined as described herein, and the course of rejection can be followed over a period of time. In this case, for example, the baseline magnitude of gene expression of the immune activation marker genes is the magnitude of gene expression in a post-transplant sample taken very shortly after the transplant. For example, an initial sample or samples can be taken within the nonrejection period, for example, within one week of transplantation and the magnitude of expression of marker genes in these samples can be compared with the magnitude of expression of the genes in samples taken after one week. In one embodiment, the samples are taken on days 0, 3, 5, 7 and 10.

In another embodiment, the post-transplant test sample comprises a blood sample obtained from the host which contains peripheral blood mononuclear cells (PBMCs) which is evaluated for the immune activation gene markers. Additionally, the PBMC sample is substantially simultaneously, or sequentially, evaluated for the presence or absence of one or more genes that are characteristic of (e.g., a marker for) an infectious agent (e.g., a virus). In this embodiment, heightened gene expression of two of the three immune activation marker genes, P, GB and FasL, concomitant with the absence of the marker for the infectious agent indicates transplant rejection. For example, to evaluate transplant rejection of a renal

-4-

allograft, the genes characteristic of the infectious agent cytomegalovirus (CMV) would be assessed. Importantly, this embodiment acts as a screening test, using easily obtained PBMCs, to differentially distinguish between acute rejection of the transplant or infection. In this case, further testing, such as with a transplant biopsy sample, will only be performed if the initial "screening" test using PBMCs is positive for rejection. Thus, transplant hosts are not submitted to invasive biopsy procedures unless it is justified (i.e., necessary to establish rejection).

In one embodiment, the biological sample is prepared for evaluation by isolating RNA from the sample, using methods described herein, and deriving (obtaining) complementary DNA (cDNA) from the isolated RNA by reverse transcription techniques. However, other methods can be used to obtain RNA, and these methods are known to those of skill in the art.

Commercially available kits for use in these methods are also known to those of skill in the art. For example, in one embodiment described herein, PBMCs are isolated from whole blood and RNA is extracted using a commercially available QIAGENTM technique. For example, QIAGEN manufactures a number of commercially available kits for RNA isolation, including RNEASY[®] Total RNA System (involving binding total RNA to a silica-gel-based membrane and spinning the RNA); OLIGOTEXTM mRNA kits (utilizing spherical latex particles); and QIAGEN total RNA kit for In Vitro Transcripts and RNA clean-up. The basic QIAGEN technique involves four steps, as set forth in Example 2, below. The QIAGEN technique can be modified to enhance the RNA isolation, by methods well-known to those of skill in the art.

The complementary DNA was coamplified with a gene-specific competitor and the quantification comprised generating a standard curve of serial dilutions of the gene-specific competitor with a constant amount of control reverse transcribed complementary DNA, thereby enabling quantification of the transcript of the gene of interest. As described herein, the gene-specific competitor is generated from phytohemagglutinin-simulated blast cells or nephrectomy tissue.

For example, the cDNA of perforin can be amplified with a pair of oligonucleotide primers comprising the nucleotides of SEQ. ID. NOS.:17 and 18 of Table 1. Likewise, the transcript of glyceraldehyde-3-phosphate dehydrogenase can be amplified with oligonucleotide primers comprising the nucleotide sequence of SEQ. ID. NOS. 1 and 2. Although these primers are specifically described herein, other suitable primers can be designed using techniques well-known to those of skill in the art. See, for example, *Current Protocols in Molecular Biology*, Volume 2, Ausubel *et al.*, eds., John Wiley & Sons, Inc. (1997) at pp. 15.0.1-1-15.8.8.

The methods described herein are useful to assess the efficacy of anti-rejection therapy. Such methods involve comparing the pre-administration magnitude of the transcripts of the marker genes to the post-administration magnitude of the transcripts of the same genes, where a post-administration magnitude of the transcripts of the genes that is less than the pre-administration magnitude of the transcripts of the same genes indicates the efficacy of the anti-rejection therapy. Any candidates for prevention and/or treatment of transplant rejection, (such as drugs, antibodies, or other forms of rejection or prevention) can be screened by comparison of magnitude of marker expression before and after exposure to the candidate. In addition, valuable information can be gathered in this manner to aid in the determination of future clinical management of the host upon whose biological material the assessment is being performed. The assessment can be performed using a biological sample (such as a biopsy or PBMCs) from the host, using the methods described herein for determining the magnitude of gene expression of the marker genes. Analysis can further comprise detection of an infectious agent.

The present invention also relates to kits for evaluating transplant rejection. For instance, the kits can include such components as means to aid in RNA isolation, cDNA derivation, RT-PCR, quantification of gene expression, and detection of an infectious agent. In one embodiment, a kit for detecting the presence of transplant rejection in a blood sample comprises means for determining the magnitude of expression of perforin, granzyme B, Fas ligand, and GAPDH in the

sample and means for determining the presence of infectious agent transcripts in the sample. For example, the kit can comprise oligonucleotide primers comprising SEQ ID NOS: 1, 2, 17, 18, 19, 20, 21 and 22. The kit can also contain other primers which can be designed using methods well-known to those of skill in the art.

- 5 Thus, as a result of the work described herein, methods are now available to accurately quantitate immune activation gene expression in biopsy tissue and peripheral blood mononuclear cells and to correlate the magnitude of expression of these genes with rejection allografts. Specifically, the evaluation of three immune activation genes in a biopsy tissue, perforin, granzyme B and Fas ligand, and
- 10 determination of heightened gene expression of two of three of these genes accurately diagnoses acute allograft rejection. Surprisingly, the evaluation of the expression of these marker genes in PBMCs, along with the evaluation of expression of an infectious agent gene, also accurately detects allograft rejection.

BRIEF DESCRIPTION OF THE DRAWINGS

- 15 Figure 1 is a chart that depicts the size and sequences of oligonucleotide primers and competitive templates (CTs) used for the quantification of 15 genes. Deletions and insertions are indicated by black and white portions of bars, respectively.

- 20 Figures 2A-F are graphs that depict the quantitative analysis of IL-2, IL-7, IL-15, perforin (P), granzyme B (GB), and Fas Ligand (FasL) gene expression in 38 transplant core biopsies taken to aid in the differential diagnosis of graft dysfunction. Biopsies were also obtained from two donor kidneys prior to reperfusion. Lines indicate sequential biopsies taken during the course of rejection before and after treatment (ACR, acute cellular rejection; NR, nonrejecting kidneys with acute
- 25 tubular necrosis or cyclosporine cytotoxicity; CR, chronic rejection; INF REC, infectious complications and recurrence of primary disease; and VASC, vascular complications).

DETAILED DESCRIPTION OF INVENTION

Renal transplantation is the treatment of choice for patients afflicted with end-stage renal disease, one of the ten leading causes of death in the United States. However, about 20-25% of the first and 30-35% of the second cadaveric renal allografts fail within one year of transplantation, despite recent advances in organ preservation, histocompatibility testing and immunosuppressive strategies.

As used herein, the term "transplantation" refers to the process of taking a cell, tissue, or organ, called a "transplant" or "graft" from one individual and placing it or them into a (usually) different individual. The individual who provides the transplant is called the "donor" and the individual who received the transplant is called the "host" (or "recipient"). An organ, or graft, transplanted between two genetically different individuals of the same species is called an "allograft". A graft transplanted between individuals of different species is called a "xenograft".

15 ACUTE ALLOGRAFT REJECTION

The single most common cause for early graft failure, especially within one month post-transplantation, is immunologic rejection of the allograft. The unfavorable impact of the rejection is magnified by the fact that: (a) the use of high-dose anti-rejection therapy, superimposed upon maintenance immunosuppression, is primarily responsible for the morbidity and mortality associated with transplantation, (b) the immunization against "public" HLA-specificities resulting from a rejected graft renders this patient population difficult to retransplant and (c) the return of the immunized recipient with a failed graft to the pool of patients awaiting transplantation enhances the perennial problem of organ shortage.

As used herein, "transplant rejection" is defined as functional and structural deterioration of the organ due to an active immune response expressed by the recipient, and independent of non-immunologic causes of organ dysfunction. The diagnosis of renal allograft rejection is made usually by the development of graft dysfunction (e.g., an increase in the concentration of serum creatinine) and morphologic evidence of graft injury in areas of the graft also manifesting

mononuclear cell infiltration. Two caveats apply, however, to the use of abnormal renal function as an indicator of the rejection process: first, deterioration in renal function is not always available as a clinical clue to diagnose rejection since many of the cadaveric renal grafts suffer from acute (reversible) renal failure in the immediate post-transplantation period due to injury from harvesting and ex-vivo preservation procedures. Second, even when immediate renal function is present, graft dysfunction might develop due to a non-immunologic cause, such as immunosuppressive therapy itself.

For example, cyclosporine (CsA) nephrotoxicity, a complication that is not readily identified solely on the basis of plasma/blood concentrations of CsA, is a common complication. The clinical importance of distinguishing rejection from CsA nephrotoxicity cannot be overemphasized since the therapeutic strategies are diametrically opposite: escalation of immunosuppressants for rejection, and reduction of CsA dosage for nephrotoxicity.

The differentiation of the diagnosis of rejection from other etiologies for graft dysfunction and institution of effective therapy is further complicated because: (a) the percutaneous core needle biopsy of renal graft, the best of available current tools to diagnose rejection is performed usually after the "fact", i.e., graft dysfunction and graft damage (irreversible in some instances) are already present, (b) the morphological analysis of the graft provides modest clues with respect to the potential for reversal of a given rejection episode, and minimal clues regarding the likelihood of recurrence ("rebound"), and (c) the mechanistic basis of the rejection phenomenon, a prerequisite for the design of therapeutic strategies, is poorly defined by current diagnostic indices, including morphologic features of rejection.

Antigen-triggered T-cell activation and the subsequent infiltration of activated CD4+ and CD8+ T-cell clones, macrophages, and natural killer (NK) cells into the graft are key events of acute allograft rejection. Although a T-cell-rich interstitial nephritis is a hallmark of acute allograft rejection, clinical rejection episodes responsive to treatment often show only a modest cellular infiltrate and similar infiltrates are observed in surveillance biopsies obtained in well-functioning

renal allografts (*Rush et al., Transplantation 57: 208-211 (1994)*); (*Rush et al., Transplantation 59: 511-514 (1994)*).

The present invention relates to the discovery that clinical rejection is associated with expression of a specific subset of T-cell-dependent immune activation genes that serve as a diagnostic indicator of rejection. Patterns of intragraft mRNA generation during a cytopathic allograft response are substantially different from those seen in other causes of graft dysfunction and may provide timely and specific information about immune events relevant to graft rejection.

More specifically, as described herein, the combined analysis of three immune activation or gene markers, perforin (P), granzyme B (GB), and Fas ligand (FasL), provides a reliable tool for the evaluation (e.g., detection, or diagnosis and follow-up) of acute cellular renal allograft rejection. The determination of increased gene transcripts of any two of these three genes indicates transplant rejection. For example, a detectable increase in gene expression of perforin and granzyme B in a kidney tissue biopsy sample, with no detectable increase in Fas ligand gene expression, is indicative of transplant rejection.

Perforins and granzyme B are proteins present in the granules of cytotoxic T lymphocytes (CTLs). Perforins are pore-forming molecules that can polymerize and perforate the cell membrane. Granzymes are a family of serine proteases that colocalizes with perforins in the CTL cytoplasmic granules. The entry of granzyme B into the target cell via perforin-created channels results in apoptosis of the target cell. Perforin-independent pathways of cell-mediated cytotoxicity, such as the interaction between Fas (APO1) antigen and Fas ligand (FasL), have been implicated in Ca^{2+} -independent systems in which the perforin monomer is unable to polymerize but cell-mediated cytotoxicity still occurs. Pavlakis, M. *Transplant. Proc.* 28(4):2019-2021 (1996).

FasL/Fas receptor-mediated CTL injury initiates target cell death via a Ca^{2+} -independent apoptotic pathway. Intragraft FasL expression, noted during murine cardiac allograft rejection, Larsen *et al., Transplantation 60:221-224 (1995)*, has not previously been investigated in clinical transplantation.

-10-

These immune activation gene markers can be obtained from a biological sample of the host. The sample can be a tissue biopsy sample (e.g., a kidney biopsy sample), or a blood sample containing peripheral blood mononuclear cells (PBMCs).

As used herein, the term "biopsy" refers to a specimen obtained by removing
5 tissue from living patients for diagnostic examination. The term includes aspiration biopsies; brush biopsies; chorionic villus biopsies; endoscopic biopsies; excision biopsies; needle biopsies (specimens obtained by removal by aspiration through an appropriate needle or trocar that pierces the skin, or the external surface of an organ, and into the underlying tissue to be examined); open biopsies; punch biopsies
10 (trephine); shave biopsies; sponge biopsies; and wedge biopsies. In one embodiment, a fine needle aspiration biopsy is used. In another embodiment, a minicore needle biopsy is used. A conventional percutaneous core needle biopsy can also be used.

As described herein, the combined analysis of three immune activation
15 genes, FasL, P, and GB, resulted in statistically significant detection of transplant rejection as compared with an analysis of any individual gene transcript. Heightened gene expression of at least two of the three CTL genes is detected only in specimens from kidneys undergoing acute cellular rejection, while low expression of these genes was confined to biopsies with other causes of graft dysfunction.
20 Elevated IL-15, FasL, and P, but not IL-7, IL-10, or GB, transcripts were occasionally found in the few chronic rejection samples processed. This finding suggests a linkage between the causation of acute and chronic rejection.

It is important to note that the mere existence of a mononuclear leukocytic infiltrate, the hallmark for the histopathological diagnosis of rejection, may not
25 necessarily be harmful for a transplant. Sequential biopsies obtained from well-functioning renal allografts at 3 and 6 months have frequently shown mononuclear leukocytic infiltrates (*Rush et al., Transplantation* 57: 208-211 (1994)); (*Rush et al., Transplantation* 59: 511-514 (1994)) without heightened expression for cytokines, P, or GB (*Lipman et al., J. Am. Soc. Nephrol.* 6: 1060
30 (1995)). Nonetheless, some of these grafts have developed subsequent chronic

rejection (Rush *et al.*, *Transplantation* 59: 511-514 (1994)). In one experimental system, an effective cyclosporine regimen did not prevent graft infiltration, but such treatment lowered the frequency of CD8+ cells expressing P and G (Mueller *et al.*, *Transplantation* 55: 139-145 (1993)). In accordance with the notion that many

5 graft-infiltrating T-cells are not cytotoxic, in histological sections of rejecting human renal allografts only few T cells show P mRNA expression (Matsuno *et al.*, *Transplant. Proc.* 24: 1306-1307 (1992); Grimm, P. C. *et al.*, *Transplantation* 59: 579-584 (1995). The number of borderline cases examined by the methods described herein support the concept that a case of a mild cellular infiltrate rejection

10 can be identified by immune activation gene expression analysis.

As described in Example 1, simultaneous analysis of intragraft gene expression of CTL effector molecules identified acute rejection (AR) in renal allografts with extraordinary sensitivity and specificity and can be introduced as a reliable diagnostic tool in the clinical management of renal transplant patients.

15 The methods described herein use competitive reverse transcription (RT)-PCR to evaluate the diagnostic accuracy of multiple immune activation gene analysis as a means to diagnose renal allograft rejection. The magnitude of intragraft gene expression of 15 immune activation genes was quantified by competitive RT-PCR in 60 renal allograft core biopsies obtained for surveillance or to diagnose

20 the etiology of graft dysfunction. The sequences of oligonucleotide primers and competitive templates that were used are shown in Figure 1 and Table 1. The results were compared with a clinicopathological analysis based upon the histological diagnosis (Banff criteria) and the response to antirejection treatment.

During acute renal allograft rejection, intragraft expression of the genes of

25 interleukin (IL)-7 ($P < 0.001$), IL-10 ($P < 0.0001$), IL-15 ($P < 0.0001$), Fas ligand ($P < 0.0001$), perforin ($P < 0.0001$), and granzyme B ($P < 0.0015$), but not IL-2, interferon γ , or IL-4, was significantly heightened. Amplified RANTES and IL-8 gene transcripts are sensitive but nonspecific markers of rejection. A simultaneous RT-PCR evaluation of perforin, granzyme B, and Fas ligand identified acute

30 rejection, including cases with mild infiltration, with extraordinary sensitivity

-12-

(100%) and specificity (100%). Effective antirejection therapy resulted in a rapid down-regulation of gene expression. Heightened gene expression of chemokines (IL-8, RANTES), non-T-cell-derived T-cell growth factors (IL-7, IL-15) and CTL-selective effector molecules was observed during rejection.

5 Thus, the quantitative RT-PCR analysis of intragraft IL-10 and IL-15 transcripts (macrophages) and the CTL-selective genes P, GB, and FasL provided a reliable and highly sensitive tool for the diagnosis of acute renal allograft rejection. RANTES and IL-8 transcripts proved to be sensitive but nonspecific indicators of rejection. IL-7 and IL-17 transcripts were seen only in rejection, but false negatives
10 were commonplace. IL-2 and IL-4 gene expression were not detected in rejection samples, while expression of IFN- γ , TGF- β 1, and CTLA4 genes was not selective for rejection.

 Further, the data described herein suggest that muted IL-7, IL-10, IL-15, and CTL gene expression can serve as an indicator for effective antirejection therapy
15 (Figure 2). This effect may occur by gene regulation or cell elimination.

 IL-2 and IL-4 were not detected during rejection episodes. An ongoing surveillance biopsy study may determine whether (i) IL-2 gene expression precedes clinically evident rejection as noted in preclinical models (O'Connell *et al.*, *J. Immunol.* 150: 1093-1104 (1993)) and (ii) IL-4 gene expression is detectable in
20 long-term stable allografts. IL-4 gene expression frequently accompanies successful long-term engraftment in preclinical trials (Strom *et al.*, *Curr. Opin. Immunol.* 8: 688-693 (1996)).

 Also as described herein, methods using RT-PCR with RNA isolated from peripheral blood mononuclear cells, or PMBCs, for gene expression of perforin (P),
25 granzyme B(GB) and Fas-ligand (FasL), also accurately detected acute rejection. The results, described in Example 2, established that the expression of these transcripts in PBMCs and core biopsy tissue correlated and this expression also correlated with the histological diagnosis. More specifically, transplant rejection can be tested in PBMCs by evaluating the magnitude of expression of the immune

-13-

activation markers P, GB and FasL, and additionally detecting the presence or absence of an infectious agent.

As used herein, an "infectious agent" refers to any agent which plays a role in infection in a graft patient. Infectious agents include bacteria such as *Escherichia coli*, *Klebsiella*, *Enterobacteriaceae*, *Pseudomonas*, and *Enterococcus*; Fungi, such as *Candida albicans*, *Histoplasma capsulatum*, and *Cryptococcus*; viruses such as Hepatitis B and C viruses, human immunodeficiency virus, and herpes-group viruses, which include herpes simplex virus type 1, herpes simplex virus type 2, varicella-zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), Human Herpesvirus 6, Human Herpesvirus 7, Kaposi's Sarcoma-associated virus (human herpesvirus 8), and Papovaviruses; and parasites, including, but not limited to, *Plasmodium falciparum*, *Toxoplasma gondii*, *strongyloides*, *stercoralis*, and *Trypanosoma cruzi*.

In one embodiment, the infectious agent analyzed is cytomegalovirus (CMV). CMV is a common and dangerous infection in transplant recipients. It generally appears on or after the end of the first post-transplant month. 50% of all renal transplant recipients presenting with fever 1 to 4 months after transplantation have evidence of CMV disease. *Harrison's Principles of Internal Medicine*, 14th. ed. Fauci, A.S. et al., McGraw-Hill (1988). CMV itself accounts for the fever in more than 2/3 of cases and thus is the predominant pathogen during this period. CMV infection may also present as arthralgias or myalgias. This infection can result in primary disease (in the case of a seronegative recipient who receives a kidney from a seropositive donor) or can present as either reactivation disease or superinfection during this interval. CMV also causes glomerulopathy and is associated with an increased incidence of other opportunistic infections (e.g., fungal infection). Because of the frequency and severity of CMV disease, considerable effort has been made to attempt to prevent and treat it in renal transplant recipients. CMV retinitis can also appear as a late infection (more than 6 months after transplantation). Furthermore, active CMV infection is sometimes associated, and confused, with transplant rejection episodes.

-14-

As described in Example 2, false positive PBMC results indicating acute transplant rejection were obtained from two patients with CMV infection. Therefore, additionally detecting the presence or absence of one or more genes characteristic of CMV can effectively discriminate between acute rejection and

5 CMV infection. For example, in addition to quantifying cDNA encoding perforin, granzyme B and Fas ligand, determining the presence or absence of cDNA encoding a gene characteristic of CMV (or other infectious agent) can be simultaneously, or subsequently determined by RT-PCR. The genetic properties of cytomegalovirus have been characterized in great detail, and are well known to those of skill in the

10 art. (See, for example, *Virology*, 2nd Ed., Fields, B.N. E., Raven Press, Ltd., N.Y. (1990)), at pages 1595-2010. Primer sequences for CMV are known and available to those of skill in the art. See Meyer König, U. *et al. J. Infectious Diseases*, Vol. 171:705-709 (1995) the contents of which are incorporated by reference in their entirety; Wright, P.A. and D. Wynford-Thomas, *J. Pathol.*, Vol. 162:99 (1990);

15 Cassol, S.A. *et al. J. Clin. Invest.*, Vol. 83:1109-1115 (1989). For example, primer sequences TCC ACG CTG TTT TGA CCT CCA TAG (CMV-sense) (SEQ ID NO:31) and GAC ATC TTT CTC GGG GTT CTC GTT (CMV anti-sense) (SEQ ID NO:32) can be used. Competitive templates can be devised to accurately quantify CMV and other infectious agents transcripts using the methods described herein for

20 the immune activation marker genes. See Clinical Laboratory Medicine, McClatchey, K.D., ed., William & Wilkins, Baltimore, MD (1994) at 165-174.

Other transplants, including lung, heart, liver and bone marrow, can be tested in a similar matter. For example, embodiment, detection of hepatitis virus transcripts can effectively discriminate between liver transplant rejection and

25 hepatitis infection. One of skill in the art can design primers for detection of hepatitis virus use in this embodiment. See *Virology, supra*, at pages 1981-2236.

As a result of the data described herein, methods are now available for the rapid and reliable diagnosis of acute rejection, even in cases with only mild cellular infiltrates. Described herein for the first time, analysis of immune activation genes

30 transcripts obtained from PBMCs, with additional analysis of CMV transcripts,

accurately detect transplant rejection. Using the methods described herein, additional early warning markers may be identified in order to utilize the sensitivity and specificity of RT-PCR to elucidate specific patterns of gene activation in vascular, chronic, and treatment-resistant rejections by refining the diagnostic criteria.

The present invention will now be illustrated by the following examples, which are not intended to be limiting in any way.

Example 1: ANALYSIS OF BIOPSY SAMPLES

BIOPSIES

Sixty kidney transplant biopsies were investigated for gene expression of chemokines (IL-8, RANTES (regulated upon activation, normal T-cell expressed and secreted), T-cell growth factors and other cytokines (IL-2, IL-4, IL-7, IL-10, IL-15, and IL-17), cell surface immunoregulatory proteins (CTLA4), cytotoxic effector molecules (P, GB, FasL), IFN- γ , transforming growth factor (TGF)- β 1, and the housekeeping protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Thirty-eight biopsies were obtained from 34 patients (25 adults and 9 children) to clarify the cause of graft dysfunction, 20 for early post-transplant surveillance and 2 from living related donor kidneys prior to reperfusion. Small portions of biopsy cores (1/10-1/2) were immediately snap frozen in liquid nitrogen at the bedside and stored at 70°C. The majority of tissue was used for histopathological analysis. Biopsies obtained to evaluate the cause of graft dysfunction were classified according to the Banff criteria (Solez *et al.*, *Kidney Int.* 44: 411-422 (1993)) as rejection (pretreatment n = 12, post-treatment n = 3), nonrejection (acute tubular necrosis, cyclosporine nephrotoxicity n = 12), chronic rejection (n = 3), recurrence of primary disease (n = 4), or other complications (n = 4). In 4 of 12 rejecting samples and 4 of 12 acute tubular necrosis samples a mild cellular infiltrate was observed (borderline cases) and the diagnosis of rejection was confirmed by a beneficial clinical response to corticosteroids or OKT3 treatment.

-16-

RNA ISOLATION

Procedures for isolation of tissue RNA and reverse transcription into cDNA were performed as described in detail (Lipman *et al.*, *J. Immunol.* 152: 5120-5127 (1994)). In brief, total RNA was isolated by tissue homogenization in guanidine isothiocyanate/2-mercaptoethanol and ultracentrifugation in CsCl. One microgram of RNA was reverse transcribed by Moloney murine leukemia virus transcriptase and diluted to a final volume of 40 μ l.

QUANTIFICATION OF GENE EXPRESSION BY COMPETITIVE TEMPLATE RT-PCR

10 Expression of specific gene transcripts identified within biopsy tissue was quantified by competitive RT-PCR as described in Lipman, M., *et al.*, *J. Immunol.*, 152:5120-5127 (1994), the contents of which is incorporated herein in its entirety by reference. Competitive RT-PCT is also described in Bunn *et al.* (U.S. Patent No. 5,213,961, incorporated herein by reference in its entirety). The cDNA derived from
15 biopsy samples was coamplified with a known amount of a mutated target gene cDNA fragment--the gene-specific competitor. Sense and antisense oligonucleotides proportionately amplified both competitor and reverse-transcribed cDNA sequences in accordance with their relative initial abundance in the PCR. (Sequences are listed in Figure 1 and Table 1 as SEQ ID NOS: 1-30).

Table 1 Sequences of oligonucleotide primers and competitive templates (CTs) used for the quantitation of 15 genes evaluated.

GENE	DIRECTION	SEQUENCE 5' TO 3'	SEQ. ID. NO.	GENE ACC
GAPDH	sense	GGTGAAGGTCGGAGTCAACG	SEQ. ID. NO:1	J04038
	antisense	CAAAGTTGTCTATGGATGACC	SEQ. ID. NO:2	
IL-2	sense	CCTCTGGAGGAAGTGCTAAA	SEQ. ID. NO:3	K02056
	antisense	ATGGTTGCTGTCTCATCAGC	SEQ. ID. NO:4	
IL-4	sense	TTCTACAGCCACCATGAGAAG	SEQ. ID. NO:5	M23442
	antisense	CAGCTCGAACACTTTGAATAT	SEQ. ID. NO:6	
IL-7	sense	TTTAGGTATATCTTTGGACTTCCTC	SEQ. ID. NO:7	J04156
	antisense	GTGTTCTTTAGTGCCCATCAA	SEQ. ID. NO:8	
IL-8	sense	TCTCTTGGCAGCCTTCCT	SEQ. ID. NO:9	M68932
	antisense	AATTCTCAGCCTCTTCAAAAATT	SEQ. ID. NO:10	
IL-10	sense	GCCGTGGAGCAGGTGAAG	SEQ. ID. NO:11	X78437
	antisense	AAGCCCAGAGACAAGATA	SEQ. ID. NO:12	
IL-15	sense	CCGTGGCTTTGAGTAATGAG	SEQ. ID. NO:13	X91233
	antisense	CAGATTCTGTTACATTCCC	SEQ. ID. NO:14	
IL-17	sense	GGAGGCCATAGTGAAGG	SEQ. ID. NO:15	U32659
	antisense	GGGTCGGCTCTCCATAG	SEQ. ID. NO:16	
perforin	sense	CGGCTCACACTCACAGG	SEQ. ID. NO:17	M31951
	antisense	CTGCCGTGGATGCCTATG	SEQ. ID. NO:18	
granzyme B	sense	GGGAAGCTCCATAAATGTCACCT	SEQ. ID. NO:19	M28879
	antisense	TACACACAAGAGGGCCTCCAGAGT	SEQ. ID. NO:20	
Fas-L	sense	GCCTGTGTCTCCTTGTA	SEQ. ID. NO:21	U11821
	antisense	GCCACCCTTCTTATACTT	SEQ. ID. NO:22	
TGF- β 1	sense	CTGCGGATCTCTGTGTCATT	SEQ. ID. NO:23	X14885-91
	antisense	CTCAGAGTGTGCTATGGTG	SEQ. ID. NO:24	
IFN- γ	sense	CCAGAGCATCCAAAAGAGTGTG	SEQ. ID. NO:25	A02137
	antisense	CTAGTTGGCCCCTGAGATAAAG	SEQ. ID. NO:26	

-18-

GENE	DIRECTION	SEQUENCE 5' TO 3'	SEQ. ID. NO.	GENE ACC
CTLA4	sense	GCAATGCACGTGGCCCAGCC	SEQ. ID. NO:27	M28879
	antisense	TTTCACATTCTGGCTCTGTTGG	SEQ. ID. NO:28	
RANTES	sense	CGGCACGCCTCGCTGTCATC	SEQ. ID. NO:29	M21121
	antisense	TGTACTCCCGAACCCATT	SEQ. ID. NO:30	

The PCR products were separated by agarose gel electrophoresis, stained with ethidium bromide, photographed in UV light with Polaroid type 55 positive/negative film, and scanned by laser densitometry (LKB Ultrascan). The ratio of densities (competitive template (CT)/reverse-transcribed cDNA) reflects the initial amounts of cDNA added (pg of competitive template per pg of reverse-transcribed cDNA). Standard curves were generated by serial dilutions of the gene-specific competitors with a constant amount of control reverse transcribed cDNA, thereby enabling quantification of the wild-type gene transcript.

Contaminating genomic DNA was easily identified by size differences, as all oligonucleotide probes were targeted to separate exons of the gene of interest. The conditions used for all competitive PCRs were identical: 94°C for 30 sec, 55°C for 20 sec, 72°C for 20 sec, 10-min extension at 72°C after 35 cycles (Perkin-Elmer Cetus 480). Competitors from phytohemagglutinin-stimulated blasts or nephrectomy tissue were generated by four different techniques (Figure 1): (i) excision of a 50- to 100-bp fragment in the center of the target gene cDNA by using appropriate restriction enzymes (GAPDH, IFN- γ , IL-10, IL-15, IL-17, P, and GB); (ii) amplification of external parts of the cDNA by two separate PCRs and religation of these fragments (CTLA4, IL-7, FasL); (iii) insertion of a short DNA fragment into the target sequence (IL-2, IL-4, TGF-1, or primer deletion (IL-4)); and (iv) one-step generation of a shortened DNA sequence by use of a specifically designed double-sense primer. Competitors were cloned in a TA vector (Invitrogen, San Diego), transfected into DH5a cells (Promega), purified, and quantitated by UV spectrometry.

Amplification of the universally expressed GAPDH gene served to confirm successful RNA isolation and reverse transcription. The magnitude of target gene expression was calculated as pg of target gene cDNA per pg of GAPDH cDNA.

Statistical analysis was performed using a Newman-Keuls test for normally distributed data or a Kruskal-Wallis test.

RESULTS

The small amount of tissue available for this study (1/10 to 1/2 of a biopsy core) proved to be sufficient for a thorough analysis of gene expression. The RNA yield ranged from 1 to 20 μ g, depending on the size of the biopsy fragment, allowing 40-800 PCRs per sample. A quantitative analysis of gene expression was necessary, because low levels of transcripts are detectable in many biopsies, while heightened expression of select genes occurred only during rejection (Figure 2A-F, Table 2).

Table 2: Quantitative analysis of intragraft gene expression for 15 immune activation genes.

Gene	Rejection	Nonrejection	P*	Sensitivity %	Specificity %
IL-2	0.0	0.0	NS	8	NA
IL-4	0.0	0.0	NS	0	0
TGF- β 1	112 \pm 87	98 \pm 78	NS	45	55
CTLA-4	577 \pm 396	228 \pm 214	<0.057	60	70
RANTES	284 \pm 147	132 \pm 104	<0.064	91	71
IFN- γ	214 \pm 194	151 \pm 130	0.007	75	67
IL-17	24 \pm 12	0.0	<0.001	83	75
IL-7	38 \pm 40	0.0	<0.001	83	100
IL-8	112 \pm 82	67 \pm	<0.0005	100	67
IL-10	451 \pm 340	24 \pm 30	<0.0005	83	89

-20-

IL-15	236 ± 162	85 ± 37	<0.0005	83	92
GB	174 ± 94	46 ± 51	<0.0015	91	86
P	1705 ± 1021	338 ± 410	<0.0001	83	92
FasL	779 ± 360	120 ± 101	<0.0001	83	92

Values are given as mean ± SD pg of target gene cDNA per pg of GAPDH cDNA. The intensity of intragraft expression of individual CTL genes was compared with histologic (Banff) criteria for establishing the diagnosis of graft rejection through an analysis of 40 transplant biopsies and, in borderline cases, clinical response to antirejection treatment. NA, not applicable.

* Statistical analysis was performed with a Newman-Keuls test for normally distributed data and a Kruskal-Wallis test for others. NS, not significant.

Heightened gene expression during acute rejection was detected for IL-7, IL-8, RANTES, IL-10, IL-15, IL-17, CTLA4, and all three CTL effector molecules, e.g., GB, P, and FasL (Figure 2A-F). GB and IL-10 expression ($P < 0.0015$ and $P < 0.0005$) proved to be significant and specific markers of acute, but not chronic, rejection, while IL-15 ($P < 0.0015$), FasL, and P ($P < 0.0001$ and $P < 0.0001$) transcription was augmented during acute allograft rejection and in some of the chronic rejection samples analyzed. The magnitude of expression of individual CTL-specific genes was not linked, and no evidence was found that the granula-dependent (GB, P) or the receptor-mediated (FasL) pathways were alternatively activated. IL-7 and IL-17 transcripts were solely, but not reliably, observed in rejecting samples, while an increase of IL-8 and RANTES mRNA was found in both rejection and graft dysfunction related to other causes. The highest level of any target gene expression measured was 4.4 times higher than the amount of GAPDH gene expression in this sample (FasL in an acute rejection episode). IL-2 and IL-4 gene expression did not accompany rejection episodes.

The accuracy of this PCR-based molecular approach to verify rejection can be considerably enhanced by a simultaneous analysis of CTL gene expression (Table

- 3). If a discriminatory level for heightened gene expression is set to the mean $\pm 95\%$ confidence interval of values observed in nonrejecting kidneys (maximum 0.07 pg/pg of GAPDH for B, 0.4 pg/pg of GAPDH for FasL, and 0.8 pg/pg of GAPDH for P), the combined analysis of all three CTL effector molecules identifies acute cellular rejection, including borderline cases with a sensitivity of 100% and a specificity of 100% in our series ($P < 0.0001$).

Table 3. Combined analysis of CTL gene expression

Gene	Rejection	Nonrejection	P*	Sensitivity %	Specificity %
P + GB, one or both up-regulated	11/12	5/28	0.00015*	91	82
FasL + GB, one or both up-regulated	12/12	4/28	<0.0001	100	85
FasL + GB + P, any two up-regulated	12/12	0/28	<0.0001*	100	100

Expression of an individual gene was deemed positive for values above the mean $\pm 95\%$ confidence interval of nonrejecting kidneys (maximum 0.07 pg/pg of GAPDH for GB and 0.4 pg/pg of GAPDH for FasL and 0.8 pg/pg of GAPDH for P).

* Statistical analysis was performed with a χ^2 test.

The magnitude of gene expression indicative for those genes associated with rejection, i.e., GB, P, and FasL, apparently declines after initiation of effective antirejection therapy (OKT3 or steroid pulses) as exemplified in the few sequential biopsy specimens analyzed (Figure 2).

-22-

Posttransplant surveillance biopsies showed similar levels of IL-7, IL-10, IL-17, and GB transcripts as compared with nonrejecting kidneys, while early (day 4 and 11) posttransplant specimens revealed that IL-15, CTLA4, P, and FasL mRNA levels were 2- to 5-fold higher and showed a tendency to decline within the first week. In a limited sampling, early posttransplant gene expression was not predictive for the later development of rejection episodes.

Example 2: ANALYSIS OF PBMCs

In a study of 16 renal allograft recipients, PBMCs were isolated from whole blood and RNA extracted by a modified QIAGENTM method. (QIAGEN Rneasy Blood Mini Kits, Cat. No. 74303, 74304 or 74305). The QIAGEN technique involves four steps: 1) a sample is combined with a suitable buffer for isolating RNA in the sample from the remaining components, e.g., 1 part whole blood, is mixed with 5 parts lysing buffer, wherein the blood cells are lysed and RNA released; 2) RNA in the sample is specifically bound to particles or a membrane; 3) the particles or membrane are washed to remove non-RNA components; and 4) the isolated RNA is eluted from the particles/membrane.

To increase the efficiency of RNA isolation from PBMCs, the second step of the QIAGEN protocol was modified as described in Example 3.

Gene expression was analyzed by reverse transcription-assisted semi-quantitative PCR in PMBC and in snap frozen transplant core biopsies and was compared to the histopathological results (AR=12 and non rejecting NR=4). Coordinate gene expression in PBMCs and the AR grafts was noted in 11/12 (92%) for P, 10/12 (83%) for GB and 9/12 (75%) for FasL. Biopsy pathology could be accurately predicted by upregulation of at least 2 of the 3 genes in PBMCs in all cases. In the NR samples, false positive gene expression in PBMCs was noted in 2/4 (50%) for P, 2/4 (50%) for GB and 1/4 (25%) for FasL when compared with intragraft gene expression. The false positive PBMC results were obtained from 2 patients with CMV infection. Biopsy histopathology in the NR specimens was accurately predicted by non-expression of 2 of the 3 genes in PBMCs in the 2

-23-

patients without CMV infection. These results indicate that the evaluation of CTL gene expression in PBMCs with evaluation of markers for CMV can be used to assess the need for allograft biopsy and evaluate acute transplant rejection.

EXAMPLE 3: METHOD FOR PROCESSING BLOOD FOR PCR ANALYSIS

5 BLOOD COLLECTION

Supplies:

2ml EDTA vacuum tubes (purple top): cat #369651 Vacutainer; Flask with ice.

Procedure:

Label EDTA tubes with Patient ID, date and time.

- 10 Draw 2ml blood into EDTA tube and carefully mix by inversion; transport on ice to the lab to be processed.*

WHITE BLOOD CELL ISOLATION

Supplies:

3 cc syringes

- 15 15 ml Sterile Conical tubes (Falcon) - Sterile polypropylene tubes (20-200 - 1000 ul)

RPMI Medium 1640: cat #11875-085 Gibco BRL

EL Buffer: cat #79217 Qiagen

Flask with liquid nitrogen: cat #2123 Lab-Line.

- 20 Ethanol (96-100%) -70% ethanol in water

14.5 M β -Mercaptoethanol (β -ME)

Lab centrifuge with rotor for 15 ml tubes - 4C Microcentrifuge with rotor for 2ml tubes

Instrumentation:

- 25 Lab centrifuge with rotor for 15 ml tubes at 4C.

-24-

Procedure:

1. Using a 3 cc syringe transfer 1-1.5 ml blood into 15 cc tube.
2. Mix the sample with 7.5 EL Buffer(1 ml/5 ml EL Buffer)
3. Incubate for 10-15 minutes on ice. Mix by vortexing briefly 2 times during
5 incubation.
If the cloudy suspension does not become translucent, prolong
incubation on ice to 20 minutes.
4. Centrifuge at 400 x g for 10 minutes at 4C, check for pellet and discard all
supernatant.
10 If pellet is red, incubate for an additional 5-10 minutes on ice after
addition of EL Buffer at step 5.
5. Add 2 ml EL Buffer to the cell pellet. Resuspend cell using a pipet to
carefully remove red cells. Add RPMI culture medium enough to fill 10cc
tube, place on ice.
- 15 6. Centrifuge again as in step 4, discard supernatant and make sure the pellet is
completely clear of blood. If not, repeat step 5.
7. Place the tube with the pellet into the canister with liquid nitrogen to snap
freeze.** Store at -70 Celsius.
8. Add 600 ul Buffer RLT (add 2ME) to pelleted while cells. Vortex or pipet to
20 mix. No while cell pellet should be visible after this step.
9. Transfer lysis solution to Qiashedder column and spin 2 min 14-18.000 rpm.
10. Discard column and add equal amount of 70% ethanol to lysis solution and
mix by pipetting.
11. Apply 500 ul to RNeasy column and spin 15 seconds with 10.000 rpm,
25 discard flow-through and repeat with any remaining fluid.
12. Discard flow-through and pipet 700 ul Wash Buffer RW1 into spin column,
centrifuge for 15 seconds 10.000 rpm and discard flow-through.
13. Place spin column in new 2 ml collection tube, pipet 500 ul of Wash Buffer
RPE into column and centrifuge as above. Discard flow-through.

-25-

14. Pipet 500 ml of wash Buffer RPE into column and centrifuge for 2 minutes full speed to dry column; discard flow-through.
 15. Transfer spin column to 1.7 ml Eppendorf tube and elute RNA with 30 ul of DEPC-treated or pure water. Spin for 1 minute 10.000 rpm. Repeat this step
5 with 30 ul of water for further elution into the same collection tube.
 16. Measure RNA by UV spectrometry and store at -70°C. If little or no RNA is eluted, again add 30 ul DEPC water to the spin column at room temperature for 10 min, then repeat step 15.
- * For optimal results, blood samples should be processed within a few hours.
- 10 ** This is a crucial step. RNA remains in snap frozen specimen stored at -70°C. However, it will rapidly degrade if the pellet defrosts or if snap freezing or storing is delayed.

EQUIVALENTS

- Those skilled in the art will recognize, or be able to ascertain using no more
- 15 than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

CLAIMS

We claim:

1. A method of evaluating transplant rejection in a host comprising detecting upregulation of the expression of at least two immune activation marker genes selected from the group consisting of: perforin, granzyme B and Fas ligand.
5
2. A method of evaluating organ rejection after transplantation in a host comprising determining the magnitude of gene expression of immune activation marker genes in a post-transplantation test sample obtained from the host and comparing this magnitude to the baseline magnitude of gene expression of said immune activation marker genes, wherein heightened gene expression of at least two of the three immune activation marker genes in the test sample indicates rejection.
10
3. The method of Claim 2 wherein the test sample is selected from the group consisting of: a tissue biopsy sample, a peripheral blood mononuclear cell sample, lymphatic fluid, peritoneal fluid and pleural fluid.
15
4. The method of Claim 2 wherein the biological sample is a tissue biopsy sample selected from the group consisting of allograft tissue and xenograft tissue.
- 20 5. The method of Claim 2 wherein the organ is a renal allograft.
6. The method of Claim 2 wherein the rejection is acute.
7. The method of Claim 2 wherein the gene expression is quantified by competitive reverse transcription polymerase chain reaction and the

-27-

magnitude of gene expression is determined by calculating the ratio of the quantity of gene expression of each immune activation marker gene to the quantity of gene expression of a constitutively expressed gene.

8. The method of Claim 7 wherein the constitutively expressed gene is
5 glyceraldehyde-3-phosphate dehydrogenase.
9. The method of Claim 2 wherein the baseline magnitude of gene expression of the immune activation marker genes is calculated as the mean magnitude of gene expression from nonrejecting hosts, and heightened gene expression is determined as above a mean +/- 95% confidence interval of these values.
- 10 10. The method of Claim 2 wherein the baseline magnitude of gene expression of the immune activation marker genes is the magnitude of gene expression in a post-transplantation sample obtained from the host within 7 days of the transplantation and the post-transplantation test sample is obtained from the host more than 7 days after transplantation.
- 15 11. The method of Claim 2 wherein the post-transplantation test sample comprises peripheral blood mononuclear cells, and the method additionally comprises detecting the presence or absence of an infectious agent in the sample, wherein heightened gene expression of two out of the three immune
20 activation marker genes concomitant with the absence of the infectious agent indicates organ rejection.
12. The method of Claim 2 wherein the infectious agent is cytomegalovirus.
13. A method of evaluating transplant rejection in a host comprising determining the magnitude of gene expression of immune activation marker genes in a test sample comprising PBMCs and comparing this magnitude to

-28-

the baseline magnitude of gene expression of the immune activation marker genes, and detecting the presence or absence of infectious agent marker genes in the sample, wherein heightened gene expression of two out of the immune activation marker genes in the test sample concomitant with the absence of said infectious agent marker genes indicates transplant rejection.

5

14. A method of detecting transplant rejection in a host comprising the steps of:
- a) obtaining a biological sample comprising cells containing immune activation marker genes and a constitutively expressed gene from the host;
 - 10 b) isolating RNA from the sample thereby obtaining isolated RNA;
 - c) obtaining complementary DNA from the isolated RNA;
 - d) quantifying cDNA encoding the immune activation marker genes perforin, granzyme B, Fas ligand and the constitutively expressed gene in the sample;
 - 15 e) calculating the ratio of the immune activation marker gene cDNA of step d) to the cDNA of the constitutively expressed gene to determine the magnitude of expression of the immune activation marker genes; and
 - f) 20 determining whether there is a heightened magnitude of expression of any two of the immune activation genes as compared to the magnitude of expression of the constitutively expressed gene; wherein a heightened magnitude of gene expression of at least two of the three immune activation genes indicates transplant rejection.
15. The method of Claim 14 wherein the constitutively expressed gene of step c) is glyceraldehyde- 3-phosphate dehydrogenase.
- 25
16. The method of Claim 14 wherein the gene transcripts of step b) are quantified by competitive reverse transcription-polymerase chain reaction.

17. The method of Claim 16 wherein perforin is amplified with oligonucleotide primers comprising the nucleotides of SEQ. ID. NO:17 and SEQ. ID. NO:18.
18. The method of Claim 16 wherein granzyme B is amplified with
5 oligonucleotide primers comprising the nucleotides of SEQ. ID. NO:19 and SEQ. ID. NO:20.
19. The method of Claim 16 wherein Fas ligand is amplified with oligonucleotide primers comprising the nucleotides of SEQ. ID. NO:21 and SEQ. ID. NO:22.
- 10 20. The method of Claim 15 wherein glyceraldehyde- 3-phosphate dehydrogenase is amplified with oligonucleotide primers comprising sequence of SEQ ID NO:1 and SEQ. ID. NO:2.
21. A method of screening for transplant rejection in a host comprising the steps of:
- 15 a) obtaining a sample of blood comprising peripheral blood mononuclear cells containing immune activation marker genes perforin, granzyme B, and Fas ligand and a constitutively expressed gene from the host;
- b) isolating RNA from the sample, thereby creating isolated RNA;
- c) obtaining complementary DNA from the isolated RNA;
- 20 d) quantifying cDNA encoding the immune activation marker genes and the constitutively expressed gene in the sample;
- e) determining the presence or absence in the sample of cDNA encoding a gene characteristic of an infectious agent;
- f) calculating the ratio of the cDNA encoding each of the immune
25 activation marker genes and the cDNA encoding the constitutively expressed gene; and

-30-

- g) determining whether there is a heightened magnitude of gene expression of any two of the immune activation genes, wherein such heightened magnitude in the absence of detectable cDNA encoding a gene characteristic of the infectious agent indicates transplant rejection.

- 5 22. The method of Claim 21 wherein the host is a human host.
23. The method of Claim 21 wherein the constitutively expressed gene is glyceraldehyde-3-phosphate dehydrogenase.
24. The method of Claim 21 wherein the infectious agent is cytomegalovirus.
- 10 25. A method of screening for the presence of transplant rejection in a host comprising the steps of:
- a) obtaining a biological sample from the host;
- b) determining the magnitude of expression of perforin, granzyme B and Fas ligand genes in the sample by competitive reverse transcription polymerase chain reaction; and
- 15 c) comparing the magnitude of expression of the perforin, granzyme B and Fas ligand genes in the sample with a normal range of values of the expression of the genes;
- wherein the magnitude of the expression of any two of the genes of step b) that is greater than the magnitude of expression of the normal range of
- 20 values indicates transplant rejection.
26. A method of assessing the efficacy of anti-rejection therapy in a transplant host comprising the steps of:
- a) quantifying the magnitude of expression of perforin, granzyme B, and Fas ligand genes in a first biological sample obtained from the host
- 25 before administration of the therapy, thereby obtaining a

-31-

pre-administration quantity of the expression of the transcripts of each gene;

- b) administering anti-rejection therapy to the host;
- c) quantifying the magnitude of expression of the genes in a second
5 biological sample obtained from the host after administration of the therapy, thereby obtaining a post-administration quantity for expression of the transcripts of each of the genes; and
- d) comparing the pre-administration quantity of the transcripts of each of
10 said genes to the post-administration quantity of the transcripts of the same gene, wherein the post-administration magnitude of the transcripts of any two of said genes that is less than the pre-administration magnitude of the transcripts of the same two genes indicate the efficacy of the anti-rejection therapy.








27. A kit for evaluating transplant rejection in a blood sample comprising means
15 for determining the magnitude of expression of perforin, granzyme B, Fas ligand and glyceraldehyde-3-phosphate dehydrogenase in the sample and means for determining the presence of infectious agent transcripts in the sample.

28. The kit of Claim 27 wherein the kit comprises oligonucleotide primers
20 comprising SEQ. ID. NOS: 1, 2, 17, 18, 19, 20, 21 and 22.

FIG. 1A

FIG. 1

FIG. 1A
FIG. 1B

gene	size cDNA and CT	method for CT	size	direction	Oligonucleotide sequence 5' to 3'	gene acc. no.
GAPDH CT		enzyme Hpa II	20	sense	GGTGAAGGTCGGAGTCAACG	J04038
IL-2 CT		insert DNA	20	antisense	CAAAGTTGTCATGGATGACC	K02056
IL-4 CT		primer deletion	20	antisense	CCTCTGGAGGAAGTGCTAAA	M23442
IL-7 CT		4-primer	21	sense	ATGGTTGCTGTCTCATCAGC	J04156
IL-8 CT		double sense	22	antisense	TTTGGTATATCTTTGGACTTCCTC	M68932
IL-10 CT		enzyme SspI	25	sense	GTGTTCTTTAGTGCCCATCAA	X78437
IL-15 CT		enzyme BstBI	18	antisense	TCTCTTGGCAGCCTTCTC	X91233
			20	antisense	AATTCTCAGCCTCTTCAAAAACCTT	
			18	sense	GCCGTGGAGCAGGTGAAG	
			18	antisense	AAGCCCAGAGACAAGATA	
			19	antisense	CCGTGGCTTTGAGTAATGAG	
			19	antisense	CAGATTCTGTACATTCCC	

IL-17 CT	471 416	enzyme EcoOIO9I	17	sense	GGAGGCCATAGTGAAGG	U32659
perforin CT	369 267	enzyme AvalI	17	antisense	GGGTGGGCTCTCCATAG	M31951
granzyme B CT	431 358		18	sense	CGGCTCACACTCACAGG	
			18	antisense	CTGCCGTGGATGCCATG	
Fas-ligand CT	321 236	enzyme DdeI	24	sense	GGGAAGCTCCATAAATGTACCT	M28879
			24	antisense	TACACACAAGAGGGCCTCCAGAGT	
TGF- β 1 CT	246 290	4-primer	18	sense	GCCTGTGTCTCCTTGTA	U11821
			18	antisense	GCCACCCTTCTTATACTT	
IFN-g CT	510 422	insert DNA	20	sense	CTGCGGATCTCTGTGTCATT	X14885-91
			20	antisense	CTCAGAGTGTTGCTATGGTG	
CTLA4 CT	629 459	enzyme AluI	22	sense	CCAGAGCATCCAAAAGAGGTG	AO2137
			22	antisense	CTAGTTGGCCCTGAGATAAAG	
Rantes CT	239 204	4-primer	20	sense	GCAATGCACGTGGCCAGCC	M28879
			22	antisense	TTTCACATTCTGGCTCTGTTGG	
		double sense	20	sense	CGGCACGCCCTCGCTGTCAATC	M21121
			19	antisense	TGTACTCCCGAACCCATTT	

FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D

5/5




FIG. 2E




FIG. 2F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/19549

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LIPMAN M. ET AL.,: "Heightened Intragraft CTL gene expression in acutely rejecting renal allografts" J. IMMUNOL., vol. 152, - 1994 pages 5120-5127, XP002092283 cited in the application see the whole document	1-28
X	STREHLAU J. ET AL.,: "Quantificative detection of immune activation transcripts as a diagnostic tool in kidney transplantation" PROC. NATL. ACAD. SCI. USA, vol. 94, - 21 January 1997 pages 695-700, XP002092284 see whole doc esp. figure 1	1-28

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

*** Special categories of cited documents:**

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 February 1999

Date of mailing of the international search report

18/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/19549

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GUERETTE B. ET AL.,: "Increased granzyme B mRNA after alloincompatible myoblast transplantation"</p> <p>TRANSPLANTATION,</p> <p>vol. 60, no. 9, - 15 November 1995 pages 1011-1016, XP002092285</p> <p>see whole doc. esp. discussion and p.1012, 1.col. 2. par.</p>	1,2
X	<p>ROBERTSON H. ET AL.,: "Renal allograft rejection-in situ demonstration of cytotoxic intratubular cells"</p> <p>TRANSPLANTATION,</p> <p>vol. 61, no. 10, - May 1996 pages 1546-1556, XP002092286</p> <p>see whole doc. esp. abstract, p.1546 2.col. 2.par.</p>	1,2
X	<p>GRIFFITHS G. M. ET AL.,: "Granzyme A and perforin as markers for rejection in cardiac transplantation"</p> <p>EUR. J. IMMUNOL.,</p> <p>vol. 21, - 1991 pages 687-692, XP002092298</p> <p>see whole doc. esp. discussion</p>	1-4,6, 9-14,25

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)